Pathological events during eariy brain development are believed to hold the key to the emergence of schizophrenia (SZ) in adulthood. Deficits in memory, attention and executive function, i.e. core domains of the psychopathology of SZ, might be causally related to dysfunctional glutamatergic and nicotinergic transmission. Kynurenine acid (KYNA), an astrocytic metabolite ofthe kynurenine pathway of tryptophan degradation, is an endogenous inhibitor of a7nACh and NMDA receptors in the brain and has been implicated in the pathology of SZ. Studies using cerebrospinal fluid (CSF) or post-mortem brain tissue of patients with SZ suggest that an excess of KYNA might play a causative role in the disease. As an endogenous antagonist at a7nAChRs and NMDARs, which are both critically involved in cognitive functions, increased KYNA levels in the brain might be especially involved in the cognitive deficits that are seen in individuals with SZ. The connection between KYNA and SZ may have a developmental dimension as several ofthe risk factors associated with SZ, including prenatal infections, result in the activation of a cytokine-responsive enzyme that catalyzes an increase in the formation of kynurenine, the direct bioprecursor of KYNA. The proposed project is based on recent studies showing that elevating brain KYNA from embryonic day (ED) 15 to postnatal day (PD) 21 results in impaired cognitive function in the adult offspring. The planned experiments are centered around the fundamentally new concept, supported by preliminary data included in this proposal, that elevating KYNA during the prenatal developmental period alone may serve as a model to study the etiology of cognitive dysfunction in SZ. The central hypothesis of this proposal is that elevated KYNA formation during prenatal development, produced from its bioprecursor kynurenine, influences the development ofthe brain and, as a result, alters kynurenine pathway dynamics, extracellular glutamate levels, and modulates hippocampal-mediated cognitive behavior in adulthood. It follows, and will be tested here, that inhibition of KYNA synthesis is a valuable therapeutic strategy to combat cognitive deficits in SZ.

Public Health Relevance

Cognitive dysfunctions are a core domain of the psychopathology of schizophrenia (SZ), a debilitating disorder affecting ~ 1 % ofthe population. The proposed work is designed to provide new insights into the role of kynurenic acid (KYNA), a neuroactive compound that is elevated in the brain of individuals with SZ, in cognition, and examine inhibition of KYNA formation as a novel strategy to overcome cognitive dysfunction.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH103222-04
Application #
9215696
Study Section
Special Emphasis Panel (ZMH1-ERB-L)
Project Start
Project End
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
$391,069
Indirect Cost
$120,557
Name
University of Maryland Baltimore
Department
Type
Domestic Higher Education
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Puvvada, Krishna C; Summerfelt, Ann; Du, Xiaoming et al. (2018) Delta Vs Gamma Auditory Steady State Synchrony in Schizophrenia. Schizophr Bull 44:378-387
Chiappelli, Joshua; Chen, Shuo; Hackman, Ann et al. (2018) Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population. Schizophr Res 194:26-31
Ryan, Meghann C; Kochunov, Peter; Sherman, Paul M et al. (2018) Miniature pig magnetic resonance spectroscopy model of normal adolescent brain development. J Neurosci Methods 308:173-182
Chiappelli, Joshua; Rowland, Laura M; Notarangelo, Francesca M et al. (2018) Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia. Neuropsychopharmacology 43:1706-1711
Secci, Maria E; Mascia, Paola; Sagheddu, Claudia et al. (2018) Astrocytic Mechanisms Involving Kynurenic Acid Control ?9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas. Mol Neurobiol :
Savransky, Anya; Chiappelli, Joshua; Fisseha, Feven et al. (2018) Elevated allostatic load early in the course of schizophrenia. Transl Psychiatry 8:246
Clark, Sarah M; Vaughn, Chloe N; Soroka, Jennifer A et al. (2018) Neonatal adoptive transfer of lymphocytes rescues social behaviour during adolescence in immune-deficient mice. Eur J Neurosci 47:968-978
Albrecht, Matthew A; Vaughn, Chloe N; Erickson, Molly A et al. (2018) Time and frequency dependent changes in resting state EEG functional connectivity following lipopolysaccharide challenge in rats. PLoS One 13:e0206985
Du, Xiaoming; Hong, L Elliot (2018) Test-retest reliability of short-interval intracortical inhibition and intracortical facilitation in patients with schizophrenia. Psychiatry Res 267:575-581
Du, Xiaoming; Rowland, Laura M; Summerfelt, Ann et al. (2018) TMS evoked N100 reflects local GABA and glutamate balance. Brain Stimul 11:1071-1079

Showing the most recent 10 out of 78 publications